Latest Study Shows Signos Drives Up to 7% Weight Loss Over 6 Months, Rivaling Real-World GLP-1 Weight Loss

• First ever real-world study of its kind evaluates how user engagement drives weight loss in adults with obesity using the Signos System with Dexcom CGM.
• Results showed that participants with higher levels of engagement in the highest obesity category achieved over 7% total body weight loss, a clinically meaningful weight loss, at six months.
• Average total body weight loss achieved at six months was on par with the average total body weight achieved in 12 months in similar GLP-1 real-world studies.

PALO ALTO, Calif.--(BUSINESS WIRE)--Signos Inc. announced today results from a real-world study demonstrating that adults with obesity without diabetes who actively engaged with the Signos System – a digital metabolic health platform integrating AI-driven coaching and Dexcom continuous glucose monitoring – achieved greater weight loss than during periods of non-engagement. The results add to the clinical evidence supporting a weight loss indication for the Signos System.

“As one of the most significant real-world analyses to date, this research offers important new insight into how sustained engagement with the Signos System with Dexcom CGM data influences weight loss outcomes,” said Jay Skyler, MD, MACP, professor of medicine, pediatrics and psychology at the Diabetes Research Institute at the University of Miami Miller School of Medicine and senior author of the study. “The results demonstrate that consistent interaction with real-time, personalized feedback can drive weight loss and highlight engagement as a critical factor in achieving effective, long-term outcomes in obesity care.”

The study showed that higher levels of engagement drove clinically meaningful weight loss at six months, with participants achieving approximately 6% total body weight loss – a benchmark that is typically reached over a longer timeframe in real-world settings with GLP-1 therapies, and those with the most to lose saw more than 7% total body weight loss. Higher engagement with the Signos System was also consistently associated with greater weight loss across BMI categories, age groups, and sexes, indicating broad effectiveness across diverse populations.

“Obesity is a complex, chronic condition that demands more than one-size-fits-all solutions,” said Sharam Fouladgar-Mercer, CEO and founder of Signos, Inc. “What stands out is the timeframe. Because the link between engagement and weight loss shows up week to week, people don't have to wait months for the scale to tell them whether their approach is working — Signos can surface that signal early, while there's still time to adjust. In fact, participants in our study achieved the same weight loss in half the time as participants of similar studies looking at the real-world effectiveness of GLP-1s.”

All study participants enrolled in the Signos System platform through the mobile app, completed a screening, and were provided a Dexcom CGM. The study evaluated 3,007 adults ages 18 and older with a BMI ≥30, including a subset of 1,147 participants in the six-month weight loss analysis. Engagement, defined as active behaviors such as logging meals, exercise, or interacting with in-app insights, was compared between engaged and non-engaged periods, with weight loss outcomes assessed by both the level and timing of engagement. Most participants identified weight loss as their primary goal, underscoring strong alignment between user intent and the outcomes evaluated.

Key outcomes from the study include:

• Participants achieved up to 7% average total body weight loss at six months, reaching the clinically meaningful ≥5% threshold.
  • Participants achieved the same average total body weight loss in six months that participants in similar studies looking at the real-world effectiveness of GLP-1s achieved in 12 months.
• Participants lost weight nearly 3x faster during weeks they engaged
• Participants experienced 1.17% weight loss per week during engaged periods compared to 0.44% per week during non-engaged periods.
• Weight loss during engagement was consistent regardless of timing, with 1.18% per week for early engagement compared to 1.12% for late engagement.

Further prospective research is needed to evaluate the long-term impact of engagement-driven digital interventions and to better establish the causal relationship between engagement and weight loss outcomes. These findings contribute to ongoing research examining the effectiveness of digitally delivered behavioral interventions in weight management.

To access the full study, titled “Engagement with an AI- and CGM-Integrated Digital Health Platform Is Associated with Clinically Significant Weight Loss,” visit the Journal of Diabetes Technology & Therapeutics.

About Signos, Inc.

Launched in 2018, Signos, Inc. is on a mission to eliminate obesity by igniting the metabolic health movement. Powered by a continuous glucose monitor (CGM), the company's mobile AI-driven system offers personalized insights into how food, movement, sleep, stress, and more affect each unique body. Signos is the only FDA-cleared CGM system for weight management and requires no prescription. For more information, visit signos.com.